Copyright
©The Author(s) 2019.
World J Gastrointest Surg. Jun 27, 2019; 11(6): 279-286
Published online Jun 27, 2019. doi: 10.4240/wjgs.v11.i6.279
Published online Jun 27, 2019. doi: 10.4240/wjgs.v11.i6.279
Author | Yr | Type of study | Patients treated with NA RCT | Resectability | Neoadjuvant regimen | % of R0 (R0/resected) | Results achieved | Conclusions |
McMasters at al[11] | 1997 | Non randomized, prospective | 5 hCCA and 4 dCCA | All unresectable | 5-FU at 300 mg/m2, EBRT to 50.4 or 45 Gy | 100% (9/9) | Recurrence for hCCA: 0% | NA RCT can safely allow R0 resection. |
Nelson et al[14] | 2009 | Retrospective | 12 (hCCA and dCCA) | 10 unresectable | 5-FU, EBRT to 50.4 Gy (11/12) ± brachitherapy (5/12) | 91% (11/12) | Better trend in 5-yr survival rate for NA RCT group | NA RCT can safely allow R0 resection. |
Jung et al[15] | 2015 | Retrospective | 12, all hCCA | All unresectable | 5-FU/Gemcitabine, EBRT to 50.4 or 45 Gy | 83,3% (10/12) | Better R0 rate for NA RCT group; no advantage in DFS and OS | NA RCT can safely allow R0 resection, without improving DFS and OS. |
Sumiyoshi et al[16] | 2018 | Retrospective | 8 hCCA | All unresectable | S-1, EBRT to 50 Gy | 71,4% (5/7) | Better DFS and OS for patients who underwent surgery after downstaging with NA RCT | NA RCT can safely allow R0 resection, improved DFS and OS for patients operated. |
Katayose et al[18] | 2015 | Non randomized, prospective | 24 (hCCA and dCCA) | All advanced, possibly resectable | Gemcitabine 600 mg/m2, EBRT to 45 Gy | 80,9 % (17/21) | R0 rate: 80.9% of patients operated, 70.8% of all patients enrolled | NA RCT followed by surgery effective and well tolerated, DFS and OS yet to determine. |
Tada et al[19] | 2012 | Case report | 1 hCCA | Unresectable | Gemcitabine + S-1 | 1/1 | R0 resection with portal resection, no recurrence at 29 mo | NA CT can allow R0 resection. |
Sano et al[20] | 2011 | Case report | 1 hCCA | Unresectable | Gemcitabine | 1/1 | R0 resection with portal and arterial resection, no recurrence at 18 mo | NA CT can allow R0 resection. |
- Citation: Frosio F, Mocchegiani F, Conte G, Bona ED, Vecchi A, Nicolini D, Vivarelli M. Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: Review of the literature. World J Gastrointest Surg 2019; 11(6): 279-286
- URL: https://www.wjgnet.com/1948-9366/full/v11/i6/279.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v11.i6.279